Insights
Search Results
Client Highlights
11.17.25
Wilson Sonsini Advises Kura Oncology on Patent and Trademark Matters Related to KOMZIFTI’s FDA Approval
On November 13, 2025, Kura Oncology (Kura) and Kyowa Kirin announced that the U.S. Food and Drug Administration (FDA) has granted full approval for KOMZIFTI™ (ziftomenib). Wilson Sonsini Goodrich & Rosati advised Kura on patent and trademark matters.
Client Highlights
11.22.24
Firm Advises Kura Oncology on Global Strategic Collaboration with Kyowa Kirin
On November 20, 2024, Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and Kyowa Kirin Co., a Japan-based global specialty pharmaceutical company, announced that they have entered into a global strategic collaboration to develop and commercialize ziftomenib, Kura’s selective oral menin inhibitor that is being investigated for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. Wilson Sonsini Goodrich & Rosati advised Kura on the transaction and has advised the company on IP matters since its founding in 2014.
Client Highlights
11.14.24
Wilson Sonsini Advises LaNova Medicines on Exclusive Global License with Merck
On November 14, 2024, Merck and LaNova Medicines, a privately held clinical-stage biotechnology company, announced that they entered into an exclusive global license for Merck to develop, manufacture, and commercialize LM-299, a novel investigational bispecific antibody targeting both programmed cell death protein-1 (PD-1) and vascular endothelial growth factor (VEGF) that is currently in Phase 1 clinical trials in China. Wilson Sonsini Goodrich & Rosati advised LaNova on the transaction.
Client Highlights
4.16.24
Wilson Sonsini Advises Kumquat Biosciences’ $1.2B Strategic Collaboration with Takeda
On April 16, 2024, Kumquat Biosciences, a leader in translating breakthrough science into first-in-class therapeutics, announced a strategic and exclusive collaboration with Takeda to develop and commercialize a novel immuno-oncology small molecule inhibitor as a mono- and/or combination-therapy. Wilson Sonsini Goodrich & Rosati advised Kumquat Biosciences on the transaction.
Client Highlights
9.12.23
Wilson Sonsini Advises Insilico Medicine on $80 Million Agreement with Exelixis
On September 12, 2023, Exelixis, Inc. and Insilico Medicine announced that the companies have entered into an exclusive license agreement granting Exelixis global rights to develop and commercialize ISM3091, a potentially best-in-class small molecule inhibitor of USP1, which has emerged as a synthetic lethal target in the context of BRCA-mutated tumors. Under the terms of the agreement, Insilico granted Exelixis an exclusive, worldwide license to develop and commercialize ISM3091, and other USP1-targeting compounds, in exchange for an upfront payment to Insilico of $80 million anticipated in the third quarter 2023. Insilico is also eligible to receive future development, commercial, and sales-based milestone payments, as well as tiered royalties on net sales.
Client Highlights
11.08.22
Wilson Sonsini Advises Insilico Medicine on $1.2 Billion Research Collaboration with Sanofi
On November 8, 2022, Insilico Medicine, a clinical-stage artificial intelligence-driven drug discovery company, announced a multi-year, multi-target strategic research collaboration with Sanofi. Under the terms of the agreement, the collaboration will leverage Insilico Medicine’s AI platform, Pharma.AI, to advance drug development candidates for up to six new targets. Wilson Sonsini Goodrich & Rosati advised Insilico Medicine on the transaction.
Client Highlights
5.10.22
Firm Advises LaNova Medicines on Exclusive License Agreement with Turning Point Therapeutics
On May 5, 2022, Turning Point Therapeutics, Inc., a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, announced that it has entered into an exclusive license agreement with LaNova Medicines Limited to develop and commercialize LM-302, a novel antibody drug conjugate (ADC) targeting Claudin18.2, in the U.S. and the rest of the world, excluding Greater China and South Korea. Wilson Sonsini Goodrich & Rosati advised LaNova on licensing and patent matters related to the transaction.
Under the terms of the licensing agreement, LaNova will receive an upfront payment of $25 million and will be eligible to receive up to an additional $195 million in development and regulatory milestone payments. In addition, LaNova is eligible to receive commercial sales milestones and tiered royalties ranging from mid-single-digit to mid-teens percentages on net sales (subject to customary deductions). As part of the agreement, both parties agreed to potentially broaden the partnership by collaborating on up to three additional ADC programs.
Claudin18.2 is a protein expressed in many gastrointestinal cancers, including gastric, gastroesophageal junction, and pancreatic cancer. LM-302, which going forward will be identified as TPX-4589, is currently in Phase 1 clinical trials in both the U.S. and China. TPX-4589 (LM-302) is a potentially first-in-class anti-Claudin18.2 ADC discovered by LaNova that suppresses cell proliferation of gastric and pancreatic cell lines with nanomolar potency in preclinical models. It also has demonstrated efficacy in gastric and pancreatic cancer xenograft models.
The Wilson Sonsini team that advised LaNova on the transaction included technology transactions partner Alex Key and Of Counsel Chi-Fei Wang, and patents and innovations Senior Of Counsel Karen Wong and Of Counsel Richard Wang.
Under the terms of the licensing agreement, LaNova will receive an upfront payment of $25 million and will be eligible to receive up to an additional $195 million in development and regulatory milestone payments. In addition, LaNova is eligible to receive commercial sales milestones and tiered royalties ranging from mid-single-digit to mid-teens percentages on net sales (subject to customary deductions). As part of the agreement, both parties agreed to potentially broaden the partnership by collaborating on up to three additional ADC programs.
Claudin18.2 is a protein expressed in many gastrointestinal cancers, including gastric, gastroesophageal junction, and pancreatic cancer. LM-302, which going forward will be identified as TPX-4589, is currently in Phase 1 clinical trials in both the U.S. and China. TPX-4589 (LM-302) is a potentially first-in-class anti-Claudin18.2 ADC discovered by LaNova that suppresses cell proliferation of gastric and pancreatic cell lines with nanomolar potency in preclinical models. It also has demonstrated efficacy in gastric and pancreatic cancer xenograft models.
The Wilson Sonsini team that advised LaNova on the transaction included technology transactions partner Alex Key and Of Counsel Chi-Fei Wang, and patents and innovations Senior Of Counsel Karen Wong and Of Counsel Richard Wang.
Client Highlights
4.21.22
Wilson Sonsini Advises Lead Investor Temasek on UPSIDE Foods' $400 Million Series C
On April 21, 2022, UPSIDE Foods (formerly Memphis Meats), a leading company in the cultivated meat, poultry, and seafood industry, announced the close of a $400 million Series C funding round that brings the company's valuation to over $1 billion. The Series C round was co-led by Temasek, a global investment company headquartered in Singapore, and the Abu Dhabi Growth Fund, a new investor. Other new investors include Baillie Gifford, Givaudan, John Doerr, SALT fund, and Synthesis Capital. They are joined by existing investors Bill Gates, Cargill, Cercano Management, CPT Capital, Dentsu Ventures, Singapore-based global investor EDBI, Kimbal and Christiana Musk, Norwest Venture Partners, SoftBank Vision Fund 2, SOSV's Indie Bio, and Tyson Foods. Wilson Sonsini Goodrich & Rosati advised Temasek on the transaction.
Client Highlights
3.28.22
Wilson Sonsini Advises InSilico Medicine on Collaboration with EQRx
On March 24, 2022, InSilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced it has entered into a strategic collaboration with EQRx, a company committed to developing and delivering innovative medicines to patients at radically lower prices. Wilson Sonsini Goodrich & Rosati represented InSilico in the transaction.
Client Highlights
1.18.22
Firm Advises Insilico Medicine on Drug Discovery Collaboration with Fosun Pharma
On January 11, 2022, Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a leading innovation-driven international healthcare group in China, and Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery and development company, announced that they have entered into a collaboration agreement to advance the discovery and development of drugs targeting a number of different targets globally through the use of AI technology. Wilson Sonsini Goodrich & Rosati advised Insilico on the transaction.
Client Highlights
7.21.21
Wilson Sonsini Advises PacBio on Omniome Acquisition, Private Placement and Intended Collaboration Expansion with Invitae
On July 20, 2021, Pacific Biosciences of California (PacBio), a leading provider of high-quality, long-read sequencing platforms, announced that it has signed a definitive merger agreement to acquire Omniome, a San Diego-based company developing a highly differentiated, proprietary short-read sequencing platform capable of delivering high accuracy. Upon closing of the acquisition, PacBio will be uniquely positioned as the only company with both highly accurate long-read and short-read sequencing platforms. The company also announced two other transactions: a private placement for aggregate proceeds of approximately $300 million in connection with the proposed acquisition, and an intent to expand a multi-year collaboration with Invitae Corporation to develop a production-scale high-throughput HiFi sequencing platform to include the sequencing technology developed by Omniome.
Client Highlights
6.22.21
Wilson Sonsini Advises InSilico Medicine on $255 Million Series C Financing
On June 22, 2021, Hong Kong-based InSilico Medicine, a global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, announced that it has closed a $255 million Series C financing led by Warburg Pincus. The financing included participation by current investors including Qiming Venture Partners, Pavilion Capital, Eight Roads Ventures, Lilly Asia Ventures, Sinovation Ventures, BOLD Capital Partners, Formic Ventures, and Baidu Ventures and new investors including CPE, Hillhouse Capital, OrbiMed, Mirae Asset, B Capital Group, Deerfield Management, Maison Capital, Lake Bleu Capital, President International Development Corporation, Sequoia Capital China, and Sage Partners.